On February 7, 2018 MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, reported that David Hansen, MabVax’s President and Chief Executive Officer will present at the BIO CEO & Investor Conference on Monday, February 12, 2018 at 11:15 a.m. EST in New York, NY (Press release, MabVax, FEB 7, 2018, View Source [SID1234523784]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As part of his presentation, Mr. Hansen will provide a corporate overview, including a clinical update on the Company’s two lead clinical development programs: (1) Its fully human antibody therapeutic product, MVT-5873, currently in a Phase 1 clinical study in combination with gemcitabine and nab-paclitaxel in first line therapy for the treatment of newly diagnosed pancreatic cancer patients. The Company remains on track to announce interim safety and response data from the MVT-5873 study early in the first quarter of 2018; and (2) the MVT-1075 program, a human antibody-based radioimmunotherapy ("RIT") product, currently being evaluated in a Phase 1 clinical trial for the treatment of pancreatic, colon and lung cancers. MabVax recently announced the completion of enrollment and dosing of all patients in the initial cohort of the Phase 1 MVT-1075 study and plans to report interim results from this study in the first quarter of 2018.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To schedule a meeting, please contact the Company through the one-on-one meeting portal.
A live audio webcast of the presentation will be available on the Events page of the Investor section of the Company’s website (www.mabvax.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days following the live presentation.